Title:  AstraZeneca, LegoChem Biosciences To Co-Develop Novel Antibiotics

Publication: Firstword Pharma

Date: 23 Dec 2012

URL: link to website 

Summary

·         AstraZeneca licensed an antibiotic drug candidate from South Korea's LegoChem Biosciences to treat drug-resistant bacterial infections, reported Asian Scientist.

·         The companies will investigate whether the combination of a cephalosporin with AstraZeneca's preclinical beta lactamase inhibitor (BLI) can break down Gram-negative bacteria's resistance to the treatment.

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).